Five years of percutaneous transluminal septal myocardial ablation

In June 1994, Ulrich Sigwart injected a small quantity of absolute alcohol into the first septal artery of a 67-year-old woman with hypertrophic obstructive cardiomyopathy. The objective of this somewhat alarming manoeuvre was to produce an area of localised myocardial infarction in the left ventricular outflow tract—in effect producing a chemical myotomy–myectomy, without recourse to open heart surgery. Five years on, the technique has been applied by a number of groups in a few hundred patients worldwide.

The birth of the Sigwart procedure (percutaneous transluminal septal myocardial ablation, transcoronary ablation of septal hypertrophy, non-surgical septal reduction) was not greeted with unanimous approval from the community of physicians treating patients with this troublesome condition. A number of eminent commentators have referred to the procedure’s “profoundly aggressive” nature and its associated “unacceptably high mortality and morbidity”.

Information is still restricted to data from relatively few patients with (inevitably) only medium term follow up. There have been five reports of the short term results of the procedure involving just under 200 patients, and three series represent the steepest portion of the learning curve. A total mortality of 3% over this period is debatable. The reported variability in pacing rates is still unclear but, anecdotally, most centres are reporting a reduction in the need for pacing, perhaps as a result of improved targeting of the ablation site with myocardial contrast echocardiography.

The deliberate creation of a myocardial infarct may create a long term substrate for arrhythmias and promote adverse ventricular remodelling. Consequently, most investigators provide data on ventricular dysrhythmias and left ventricular cavity size. Early ventricular arrhythmias occur in fewer than 2% of patients, usually without significant sequelae. There have been no reports of late onset ventricular arrhythmias to date. Faber et al report no significant change in left ventricular end diastolic diameter over 30 months’ follow up, but another longer term report did detect a small (4 mm) but significant increase in left ventricular end diastolic diameter with time.

In June 1994, Ulrich Sigwart injected a small quantity of absolute alcohol into the first septal artery of a 67 year old woman with hypertrophic obstructive cardiomyopathy. The wisdom of generalising from the early point in the technique’s development; it is now five years old, what do we know of the results of this interventional “enfant terrible” and how safe is it?

Five years of percutaneous transluminal septal myocardial ablation (AV) block four days after the procedure. Over the longer term#### End of Document

**Editorial**

Five years of percutaneous transluminal septal myocardial ablation

In June 1994, Ulrich Sigwart injected a small quantity of absolute alcohol into the first septal artery of a 67-year-old woman with hypertrophic obstructive cardiomyopathy. The objective of this somewhat alarming manoeuvre was to produce an area of localised myocardial infarction in the left ventricular outflow tract—in effect producing a chemical myotomy–myectomy, without recourse to open heart surgery. Five years on, the technique has been applied by a number of groups in a few hundred patients worldwide.

The birth of the Sigwart procedure (percutaneous transluminal septal myocardial ablation, transcoronary ablation of septal hypertrophy, non-surgical septal reduction) was not greeted with unanimous approval from the community of physicians treating patients with this troublesome condition. A number of eminent commentators have referred to the procedure’s “profoundly aggressive” nature and its associated “unacceptably high mortality and morbidity”. Clearly such comments were made at a very early point in the technique’s development; it is now five years old, what do we know of the results of this interventional “enfant terrible” and how safe is it?

Information is still restricted to data from relatively few patients with (inevitably) only medium term follow up. There have been five reports of the short term results of the procedure involving just under 200 patients, and three series represent the steepest portion of the learning curve. A total mortality of 3% over this period is debatable. The reported variability in pacing rates is still unclear but, anecdotally, most centres are reporting a reduction in the need for pacing, perhaps as a result of improved targeting of the ablation site with myocardial contrast echocardiography. It does not seem unreasonable to suppose that the rate of pacemaker implantation after the Sigwart procedure will become broadly similar to that seen after myotomy–myectomy (around 10%).

The deliberate creation of a myocardial infarct may create a long term substrate for arrhythmias and promote adverse ventricular remodelling. Consequently, most investigators provide data on ventricular dysrhythmias and left ventricular cavity size. Early ventricular arrhythmias occur in fewer than 2% of patients, usually without significant sequelae. There have been no reports of late onset ventricular arrhythmias to date. Faber et al report no significant change in left ventricular end diastolic diameter over 30 months’ follow up, but another longer term report did detect a small (4 mm) but significant increase in left ventricular end diastolic diameter with time. While encouraging, the follow up intervals of these reports are too brief to provide complete reassurance that the beneficial early haemodynamic effects of the Sigwart procedure are not bought at the expense of longer term ventricular function.

**Effectiveness**

There seems little doubt that the Sigwart procedure has equivalent efficacy to surgical techniques in the reduction of left ventricular outflow tract obstruction. Pooled data suggest a reduction in gradient from a mean of 60 mm Hg to 14 mm Hg, and studies with longer follow up do not show any recurrence of obstruction with time.

Symptomatic rather than haemodynamic changes following a new interventional procedure are extremely difficult to assess as a consequence of a substantial placebo effect, and neither surgery nor the Sigwart procedure can be subjected to the rigorous double blind evaluation that has diminished enthusiasm for dual chamber pacemaker treatment for hypertrophic cardiomyopathy. Bearing these important caveats in mind, all three longer term reports show significant and maintained improvements in symptoms with a mean increase of just over one NYHA (New York Heart Association) functional class. More importantly, objective tests of exercise capacity show increases of around 40% in exercise performance over follow up.

We are now at the stage when the Sigwart procedure should be compared with surgical myotomy–myectomy in a randomised trial. This will not be an easy undertaking. First, there may be a tendency for patients to opt for the less aggressive technique rather than randomisation, arguing (not unreasonably) that surgery can be performed if ablation fails. Second, the number of patients for whom either technique is appropriate is small. The success of the technique in the future depends critically on correct patient selection. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy is compatible with a normal life expectancy in some patients and there is no evidence that relief of obstruction has an impact on prognosis. It follows that myotomy–myectomy or the Sigwart procedure should be performed only on patients...
Acupuncture anaesthesia for open heart surgery

Open heart surgery under acupuncture anaesthesia is depicted on this 8 cent Chinese stamp issued in 1975 as part of a set of four stamps to commemorate the successful integration of traditional Chinese medicine and modern Western medicine in the treatment of various diseases. The four Chinese characters at right lower corner of the stamp stand for acupuncture anaesthesia. The other three stamps in the set feature such surgical feats as re plantation of severed limbs, application of small soft splints for fractures, and cataract surgery.

The patient in this stamp was a 15 year old girl with congenital ventricular septal defect. The Chinese made disc oxygenator for total cardiopulmonary bypass can be seen on the right. The anaesthetist who performed the acupuncture—two fine needles inserted in both wrists and a further two in the anterior chest wall at both subclavicular areas—was at the patient’s head; he was a practitioner of Chinese traditional medicine. The surgeon on the patient’s left was Professor Yi-shan Wang, my schoolmate in St John’s University School of Medicine, Shanghai, China, and the surgeon on the patient’s right was Dr Chun-xiu Yeh, my classmate in the same school.

From the historical record of Huangdi Neijing (The Yellow Emperor’s Classic), acupuncture has been used in China as a therapeutic measure for at least 2000 years. However, acupuncture as anaesthesia is a relatively recent development. It has a sound physiological and neurochemical basis. Although acupuncture anaesthesia is still widely used in China for craniotomy and thyroidectomy, it is not as frequently employed today for open heart operations in China as it was in the 1970s. The main reason is that the patients have to undergo lengthy preoperative training to practice slow and deep abdominal and diaphragmatic breathing required during the operation to overcome the positive atmospheric pressure in the event that the pleural cavity is inadvertently entered; another prerequisite is that the surgeons must be extremely gentle, meticulous, and speedy. Conventional anaesthesia obviates both of these requirements and is thus preferred by younger surgeons.

There is a phrase in Chinese shown on the stamp, 明心, which means “being happy”. Literally translated, Kai Xin actually means to open the heart. This remarkable stamp certainly depicts such a happy moment in the history of Chinese cardiac surgery. To transform acupuncture from a form of traditional medicine for relief of pain to a form of anaesthesia for open heart surgery is truly a great leap forward.

TSUNG O CHENG
Professor of Medicine, The George Washington University Medical Center, Washington, DC 20037, USA

STAMPS IN CARDIOLOGY

CHARLES J KNIGHT
London Chest Hospital, Bonner Road, London E2 9JX, UK


Five years of percutaneous transluminal septal myocardial ablation

CHARLES J KNIGHT

*Heart* 2000 83: 255-256
doi: 10.1136/heart.83.3.255

Updated information and services can be found at:
http://heart.bmj.com/content/83/3/255

These include:

**References**
This article cites 12 articles, 5 of which you can access for free at:
http://heart.bmj.com/content/83/3/255#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Epidemiology (3752)
- Clinical diagnostic tests (4779)
- Drugs: cardiovascular system (8842)
- Acute coronary syndromes (2742)
- Hypertrophic cardiomyopathy (314)
- Venous thromboembolism (495)
- Echocardiography (2127)
- Interventional cardiology (2933)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/